The Epi-TAF for Tenofovir Disoproxil Fumarate?

被引：15

作者：

Walensky, Rochelle P. ^{[1
,2
,3
,4
]}

Horn, Tim H. ^{[5
]}

Paltiel, A. David ^{[6
]}

机构：

[1] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, 50 Staniford St,9th Flr, Boston, MA 02114 USA

[2] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA

[3] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA

[4] Harvard Univ, Ctr AIDS Res, Sch Med, Boston, MA 02115 USA

[5] Treatment Act Grp, New York, NY USA

[6] Yale Univ, Sch Publ Hlth, New Haven, CT USA

来源：

CLINICAL INFECTIOUS DISEASES | 2016年 / 62卷 / 07期

关键词：

tenofovir disoproxil fumarate; tenofovir alafenamide; costs; cost-effectiveness; generics;

D O I：

10.1093/cid/civ1000

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Approximately 84% of human immunodeficiency virus (HIV)-infected US residents on antiretroviral therapy currently receive some form of tenofovir disoproxil fumarate (TDF) as part of their HIV treatment regimen. The TDF analogue tenofovir alafenamide (TAF) has demonstrated equal efficacy but with decreased renal injury and bone mineral density loss compared with TDF. We examine how much more society ought to be willing to pay for TAF over TDF, in exchange for its improved toxicity profile. Using cost-effectiveness methods, we find that current conditions warrant an annual premium of up to $1000 over the average wholesale price (AWP) of TDF. Once generic coformulations of tenofovir/lamivudine become accessible, however, the appropriate premium for TAF will likely merit a downward adjustment, using generic TDF-based costs as the benchmark.

引用

页码：915 / 918

页数：4

共 50 条

[1] Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
De Clercq, Erik
[J]. BIOCHEMICAL PHARMACOLOGY, 2016, 119 : 1 - 7
[2] Tenofovir disoproxil fumarate
[J]. Reactions Weekly, 2012, 1432 (1) : 44 - 44
[3] Tenofovir Disoproxil Fumarate
Therese M. Chapman
Jane K. McGavin
Stuart Noble
[J]. Drugs, 2003, 63 : 1597 - 1608
[4] Tenofovir disoproxil fumarate
Grim, SA
Romanelli, F
[J]. ANNALS OF PHARMACOTHERAPY, 2003, 37 (06) : 849 - 859
[5] Tenofovir disoproxil fumarate
Nestor, RJ
[J]. ANNALS OF PHARMACOTHERAPY, 2003, 37 (7-8) : 1148 - 1148
[6] Tenofovir disoproxil fumarate
Gallant, JE
Deresinski, S
[J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (07) : 944 - 950
[7] Safety of tenofovir alafenamide (TAF) in patients with a history of proximal renal tubulopathy on tenofovir disoproxil fumarate (TDF)
Hamzah, L.
Jones, R.
Bailey, A.
Williams, D.
Johnson, M.
Ibrahim, F.
Musso, C.
Burling, K.
Campbell, L.
Post, F.
[J]. HIV MEDICINE, 2019, 20 : 8 - 9
[8] Emtricitabine/tenofovir disoproxil fumarate
不详
[J]. Drugs in R & D, 2004, 5 (3) : 160 - 161
[9] Switching Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide Fumarate (TAF) in Hepatitis B/HIV Co-Infection: A Feasibility Study
Lok, James
Veloz, Maria Fernanda Guerra
Byrne, Ruth
Carey, Ivana
Childs, Kate
Agarwal, Kosh
Nelson, Mark
[J]. CLINICAL THERAPEUTICS, 2024, 46 (02) : 159 - 163
[10] Emtricitabine/tenofovir disoproxil fumarate
Pozniak, A
[J]. DRUGS, 2004, 64 (18) : 2083 - 2084

← 1 2 3 4 5 →